Invitrogen™ Kit ELISA™ Instant human osteoprotein (TNFRSF11B)

Ref.: BL-RE-107343Manufacturer ref.: BMS2021INST 128 Tests
€774.00 excl. VAT

The ELISA human osteoprotegrin test (TNFRSF11B) (human OPG) quantifies human OPG in serum, plasma, cell culture supernatants or other human body fluids. The dosage will recognize exclusively human OPG...

Accession number
O00300
Dose range
15.6-1.000 pg/ml
Sensitivity of the dosage
2.5 pg/ml
Conjugate
Biotin
Product type
Kit ELISA
Brand
Invitrogen

The ELISA human osteoprotegrin test (TNFRSF11B) (human OPG) quantifies human OPG in serum, plasma, cell culture supernatants or other human body fluids. The dosage will recognize exclusively human OPG...

The ELISA human osteoprotegrin test (TNFRSF11B) (human OPG) quantifies human OPG in serum, plasma, cell culture supernatants or other human body fluids. The dosage will recognize only natural and recombinant human OPG. The principle of the solid-phase L-ELISA sandwich method for human OPG (an immuno-enzymatic test) is designed to measure the amount of the target bound between a pair of matched antibodies. A target-specific antibody was pre-assembled in the wells of the supplied microplate. Samples or controls are then added to these wells and bind to the immobilized antibody (capture). The sandwich is formed by binding the second antibody (detector) to the target on an epitope different from the capture antibody. An antibody conjugated with the enzyme binds the formed sandwich. After incubation and washing steps to remove the microplate from unbound substances, a substrate solution reacts with the enzyme-antibodies-target complex to produce a measurable signal. The intensity of this coloured product is directly proportional to the concentration of TP (p) present in the original sample. Rigorous validation Each batch manufactured from this ELISA kit is tested for quality for criteria such as sensitivity, specificity, accuracy and batch-to-batch consistency. See the product manual for more information on validation.

Act as a decoy receptor for TNFSF11/RANKL and thus neutralize its function in the osteoclastogenesis. Prevents osteoclast activation and promotes osteoclast apoptosis in vitro. Bone homeostasis appears to depend on the local ratio of TNFSF11 to TNFRSF11B. May also play a role in preventing blood calcification. May act as a decoy receptor for TNFSF10/TRAIL and protect against apoptosis. TNFSF10/TRAIL bond blocks inhibition of osteoclastogenesis.

Sensitivity

Sensitivity of the dosage: 2.5 pg/ml.

Measurement range

Dose range: 15.6-1.000 pg/ml.

Duration of dosing

Total duration of dosing: 3 h 10 min.

Reproducibility

Coefficient of intra-dose variation 7%, inter-dose 8%.

Target

Target: Human.

Technical specifications

General
BrandInvitrogen
Supplier ref. (Fisher Scientific)15581507
Specifications
Accession numberO00300
Dose range15.6-1.000 pg/ml
Sensitivity of the dosage2.5 pg/ml
ConjugateBiotin
Product typeKit ELISA
Type of sampleSerum, Surnatant, Supernatant
Target speciesHuman
For use with (application)ELISA
For use with (equipment)Colorimetric microplate reader
Genetic identification (Enter)4982
Gene symbol(s)OCIF,OPG,PDB5,TR1
Coefficient of inter-dose variation8%
Coefficient of intra-dose variation7%
Contents of kitsMicroplate with 96 pre-coated wells, Biotinylated detection antibody, Sample diluent, Sample diluent, lyophilized, Wash buffer concentrate, Wash buffer concentrate, Substrate solution, 10x lysis pad, Adhesive plate covers, Adhesive plate covers
Marker or dyeHRP
Quantity128 Tests
Regulatory statusRUO
SynonymOsteoprotegerin, member 11b of the TNF-R superfamily
TargetHuman
Test time20 min
Physical characteristics
Volume of samplePlasma, 50 μl; Serum, 50 μl; Supernatant, 50 μl
Storage and shipping
Storage conditions-20°C
Total duration of dosing3 h 10 min

Origin and customs

Manufacturer ref.BMS2021INST
Country of originAutriche
HS customs code3002 15 00 00
A question or a specific configuration?
Contact us for a quote.